Research presented at the ASCO Annual Meeting 2025 highlighted potential new standards of care and other advances in ...

Appendix cancer, once rare, is now rising sharply among younger people. Firstpost brings out an expert’s views on the risk ...

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes ...

There is currently a trial at the National Institutes of Health involving a revolutionary new treatment for cancer called Tumor-Infiltrating Immunotherapy. It uses one’s own immune cells to fight ...

A rare gastrointestinal cancer is rising sharply among Gen X and Millennials, prompting experts to call for more research.

Colorectal cancer is the second-leading cause of cancer related death in the U.S., with nearly 53,0001 fatalities expected in 2025. While the burden of this disease is significant, advancements in ...